Monthly Archives: March 2011

U.S. Inter-Agency Group takes on Counterfeit Pharmaceuticals

The Office of the Intellectual Property Enforcement Coordinator released an Inter-Agency report partnering with the Food and Drug Administration, U.S. Customs and Border Protection, U.S. Immigration and Customs Enforcement, and the Departments of Justice, State, and Commerce and USAID. The report highlights the Administration’s efforts to combat counterfeit pharmaceuticals listing various Department initiatives and in some cases providing actual budget numbers (State Department budgets $1.3 million in 2011 to combat counterfeit pharmaceuticals).  Finally, the report Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , , ,

Anitbody Deals Peaked in 2007

Antibody and antibody-like scaffold molecules have been on the pharma licensing radar for some time. The pharma business development interest in these drug candidates stems largely from the targeted mechanisms of action, structural uniqueness of the molecules, strong IP, and portfolio diversification benefits. To analyze deal trends in this niche area of biotechnology, we screened the Windhover/Elsevier Strategic Transactions Database for “Biotechnology” deals, with “Antibody” or “Large Molecule” identifiers, from 2007-2010. From this initial list, Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Poised to Partner with Chinese Leaders to Grow Biotech

This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

BIO Hails Senate Passage of America Invents Act

BIO Hails Senate Passage of America Invents Act Bipartisan, consensus-oriented approach will strengthen nation’s patent system and spur innovation, job creation Washington, D.C. (March 8, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage today of the America Invents Act (S. 23) by the U.S. Senate: “BIO commends the Senate for its overwhelming passage of the America Invents Act by a vote of 95-5.  We appreciate Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,

A Partner in Partnering: BIO and the China Healthcare Investment Conference

If you’re attending the China Healthcare Investment Conference this month, you’ll probably notice something familiar. BIO has partnered with the Lychee Group to use the One-on-One Partnering System during their event! The event focuses on the most influential Chinese and global thought leaders to promote the development of the Chinese healthcare market, and all attendees will now be able to send requests, schedule meetings, and connect with one another in private meetings. As with all Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , ,